Overview
A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART). This study also examines the effect tucaresol has on viral load (level of HIV in the body) when tucaresol is used with HAART.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Aaron Diamond AIDS Research Center
Criteria
Inclusion CriteriaPatients may be eligible for this study if they:
- Are at least 18 years old.
- Are HIV-positive.
- Have more than 300 CD4 T cells/microL at screening.
- Are taking certain anti-HIV drugs.
- Have been taking these anti-HIV drugs successfully for at least 6 months.
- Do not expect to change their anti-HIV therapy while they are in the study.
- Have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy.
- Have viral load that cannot be detected at screening and baseline tests.
- Are able to complete weekly visits.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Cannot give informed consent.
- Have abnormal laboratory test results at baseline.
- Are pregnant or breast-feeding.
- Have had certain short-term or long-term illnesses (such as heart disease, sickle cell
disease, anemia, or lung problems).
- Have received a vaccination within the 30 days prior to enrollment.
- Have received any other experimental drug within 60 days of enrollment.
- Are taking abacavir (Ziagen, GW1592) or drugs that affect the immune system, such as
IL-2, GM-CSF, corticosteroids, or cyclosporine.
- Have a history of tumors.
- Are actively using illegal drugs (methadone is allowed).
- Have hepatitis B or hepatitis C.